Brought to you by 
Maxwell Biotech Venture invests in Sequella for rights to TB therapeutic
09 May 2014
Executive Summary
In return for an equity investment, development and commercial milestones, and royalties, antibiotics developer Sequella Inc. has licensed Maxwell Biotech Venture Fund rights to its Phase II tuberculosis compound SQ109 in Russia and the CIS countries of Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine. The transaction has a potential value of $50mm. SQ109 was discovered by Sequella in partnership with the National Inst. of Allergy & Infectious Diseases.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Other
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Maxwell Biotech Venture invests in Sequella for rights to TB therapeutic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice